211 related articles for article (PubMed ID: 21327421)
1. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
[TBL] [Abstract][Full Text] [Related]
3. Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza MR; Skougaard K; Wihl J; Keldsen N; Damkier P; Peterson C; Vach W; Brøsen K
Basic Clin Pharmacol Toxicol; 2012 Feb; 110(2):199-204. PubMed ID: 21955855
[TBL] [Abstract][Full Text] [Related]
4. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
[TBL] [Abstract][Full Text] [Related]
6. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Hertz DL; Motsinger-Reif AA; Drobish A; Winham SJ; McLeod HL; Carey LA; Dees EC
Breast Cancer Res Treat; 2012 Jul; 134(1):401-10. PubMed ID: 22527101
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas.
Johnatty SE; Beesley J; Gao B; Chen X; Lu Y; Law MH; Henderson MJ; Russell AJ; Hedditch EL; Emmanuel C; Fereday S; Webb PM; ; Goode EL; Vierkant RA; Fridley BL; Cunningham JM; Fasching PA; Beckmann MW; Ekici AB; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Brown R; Paul J; Lambrechts S; Despierre E; Vergote I; Lester J; Karlan BY; Heitz F; du Bois A; Harter P; Schwaab I; Bean Y; Pejovic T; Levine DA; Goodman MT; Camey ME; Thompson PJ; Lurie G; Shildkraut J; Berchuck A; Terry KL; Cramer DW; Norris MD; Haber M; MacGregor S; deFazio A; Chenevix-Trench G
Gynecol Oncol; 2013 Oct; 131(1):8-14. PubMed ID: 23917080
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.
Bergmann TK; Brasch-Andersen C; Gréen H; Mirza M; Pedersen RS; Nielsen F; Skougaard K; Wihl J; Keldsen N; Damkier P; Friberg LE; Peterson C; Vach W; Karlsson MO; Brosen K
Pharmacogenomics J; 2011 Apr; 11(2):113-20. PubMed ID: 20368717
[TBL] [Abstract][Full Text] [Related]
9. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
Fransson MN; Gréen H; Litton JE; Friberg LE
Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
Yamaguchi H; Hishinuma T; Endo N; Tsukamoto H; Kishikawa Y; Sato M; Murai Y; Hiratsuka M; Ito K; Okamura C; Yaegashi N; Suzuki N; Tomioka Y; Goto J
Int J Gynecol Cancer; 2006; 16(3):979-85. PubMed ID: 16803472
[TBL] [Abstract][Full Text] [Related]
11. Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity.
Lee MY; Apellániz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brøsen K; Green H; Rodríguez-Antona C; Ingelman-Sundberg M
Pharmacogenomics; 2015; 16(9):929-37. PubMed ID: 26115084
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.
Gréen H; Khan MS; Jakobsen-Falk I; Åvall-Lundqvist E; Peterson C
J Pharm Sci; 2011 Oct; 100(10):4205-9. PubMed ID: 21702053
[TBL] [Abstract][Full Text] [Related]
13. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
Wu H; Kang H; Liu Y; Tong W; Liu D; Yang X; Lian M; Yao W; Zhao H; Huang D; Sha X; Wang E; Wei M
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1449-62. PubMed ID: 22526155
[TBL] [Abstract][Full Text] [Related]
14. Expression and activity of taxane-metabolizing enzymes in ovarian tumors.
DeLoia JA; Zamboni WC; Jones JM; Strychor S; Kelley JL; Gallion HH
Gynecol Oncol; 2008 Feb; 108(2):355-60. PubMed ID: 18063021
[TBL] [Abstract][Full Text] [Related]
15. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
16. Influence of (C1236T and C3435T) Polymorphisms of ABCB1 Gene on Chemotherapy Treatment Outcome and Toxicity in Breast Cancer Patients.
Gudur RA; Bhosale SJ; Gudur AK; Kale SR; More AL; Datkhile KD
Asian Pac J Cancer Prev; 2024 May; 25(5):1567-1577. PubMed ID: 38809628
[TBL] [Abstract][Full Text] [Related]
17. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Tian C; Ambrosone CB; Darcy KM; Krivak TC; Armstrong DK; Bookman MA; Davis W; Zhao H; Moysich K; Gallion H; DeLoia JA
Gynecol Oncol; 2012 Mar; 124(3):575-81. PubMed ID: 22112610
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
Knez L; Košnik M; Ovčariček T; Sadikov A; Sodja E; Kern I; Cufer T
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1551-60. PubMed ID: 22543673
[TBL] [Abstract][Full Text] [Related]
19. Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients.
Rizzo R; Spaggiari F; Indelli M; Lelli G; Baricordi OR; Rimessi P; Ferlini A
Breast Cancer Res Treat; 2010 Nov; 124(2):593-8. PubMed ID: 20632082
[TBL] [Abstract][Full Text] [Related]
20. GSTP1 and ABCB1 Polymorphisms Predicting Toxicities and Clinical Management on Carboplatin and Paclitaxel-Based Chemotherapy in Ovarian Cancer.
Ferracini AC; Lopes-Aguiar L; Lourenço GJ; Yoshida A; Lima CSP; Sarian LO; Derchain S; Kroetz DL; Mazzola PG
Clin Transl Sci; 2021 Mar; 14(2):720-728. PubMed ID: 33326171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
